ACCESSWIRE
United States
Tel: 1-888-952-4446
Website: https://www.accesswire.com/
Email: DigitalSales@accesswire.com
About ACCESSWIRE
ACCESSWIRE is a global newswire and communications network, delivering regional, national and international news to thousands of customers across the world. ACCESSWIRE serves both public and private companies, disseminating their full-text and rich media press releases to news media, financial markets, investors, information websites, databases, bloggers and social networks.
The press release platform offers an exceptionally cost-effective Fair Disclosure, Regulation FD news dissemination and media outreach service.
Platform users can easily publish rich media assets, such as video, audio and images, and build their own distribution to the most-needed outlets. Users can effectively distribute an earnings announcement, product launch, community message, M&A transaction or corporate update to the worldwide news network.
Corporate issuers and their constituents find the cloud-based platforms and related services particularly robust — from document creation through dissemination to regulatory bodies, platforms and shareholders.
Contact ACCESSWIRE’s parent company, Issuer Direct, to learn more.
3658 articles with ACCESSWIRE
-
Interdepartmental Testing of the Kidney Function Biomarker PenKid in Routine Care at Heidelberg University Hospital and the Heidelberg Kidney Center
8/26/2022
The diagnostic company SphingoTec GmbH announces the introduction of novel biomarker penKid in the clinical routine management of patients on a test basis in a total of four units at the University Hospital Heidelberg and Heidelberg Kidney Center.
-
Moderna Sues Pfizer and BioNTech for Infringing Patents Central to Moderna's Innovative mRNA Technology Platform
8/26/2022
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today is filing patent infringement lawsuits against Pfizer and BioNTech in the United States District Court for the District of Massachusetts and the Regional Court of Düsseldorf in Germany.
-
Evotec Expands Clinical and Commercial Drug Substance Manufacturing with Acquisition of Central Glass Germany
8/25/2022
Evotec SE announced that the Company expands its clinical and commercial manufacturing platform for small molecule therapeutics by acquiring Central Glass Germany GmbH from the Japanese chemical manufacturing company Central Glass Co. Ltd.
-
Jaguar Health Secures Additional Capital Through Sale of Royalty Rights Related to Future Crofelemer and Lechlemer Revenue Stream
8/25/2022
Jaguar Health, Inc. today announced that the Company has entered into a royalty interest purchase agreement with Utah-based Streeterville Capital, LLC ("Streeterville").
-
IIOT-OXYS, Inc. Reports Second Quarter Results and Upcoming Investor Conference Call
8/25/2022
IIOT-OXYS, Inc. (OTC PINK:ITOX) announced its financial results for its second quarter ended June 30, 2022, and an upcoming Investor Conference Call on Tuesday, August 30, 2022.
-
BioInvent International AB: Interim Report January-June 2022
8/25/2022
The second quarter 2022 was eventful for BioInvent, delivering a deal with the US biotech company Exelixis, positive progress in our clinical portfolio and strengthened organizational leadership.
-
AlzeCure Publishes its Interim Report for January – June 2022
8/25/2022
AlzeCure Pharma AB announced that its interim report for the period January - June 2022 is now available on the company's website.
-
Relief Therapeutics Files Registration Statement on form F-1 with the U.S. Securities and Exchange Commission
8/24/2022
RELIEF THERAPEUTICS Holding SA, announced today that it has filed a Registration Statement on Form F-1 under the Securities Act of 1933 with the U.S. Securities and Exchange Commission relating to a proposed offering of its ordinary shares in the form of American Depositary Shares.
-
XVIVO Capital Markets Day 2022
8/24/2022
XVIVO invites to its digital Capital Markets Day, September 21, 2022.
-
Spago Nanomedical interim report January-June 2022
8/24/2022
Spago Nanomedical raised approximately SEK 58.4 million before transaction costs in the Rights Issue, which was subscribed to a total of 94.6 percent.
-
IRLAB Publishes Interim Report for the Period January–June 2022
8/24/2022
IRLAB Therapeutics AB, a clinical-stage biopharmaceutical company discovering and developing novel treatments for the most troublesome symptoms of Parkinson's disease, announced that the company's interim report for the period January - June 2022, has been published.
-
Pressure BioSciences Secures Pivotal Cosmeceuticals Partnership for UST Platform With Dr. Denese SkinScience, 20-Year Leader With Over $0.5 Billion in QVC Sales
8/24/2022
Pressure BioSciences, Inc. today announced the Company's agreement to team with science-driven skincare industry leader Dr. Adrienne Denese, M.D., Ph.D.
-
Dermata to Participate in the Gilmartin Group Emerging Growth Company Showcase
8/24/2022
Dermata Therapeutics, Inc., a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, announced that Dermata will participate in the Gilmartin Group Emerging Growth Company Showcase, being held on August 31, 2022.
-
Vimian’s Interim Report for the Second Quarter of 2022
8/24/2022
Vimian delivers another solid quarter with 70 per cent revenue growth to EUR 67 million, and an adjusted EBITA margin of 26.4 per cent.
-
Pieris Pharmaceuticals Announces Presentation of Preclinical Data for Inhaled Jagged-1 Inhibitor PRS-400 at ERS
8/24/2022
Pieris Pharmaceuticals, Inc. today announced the presentation of preclinical data for PRS-400, an inhaled Jagged-1 Anticalin protein the Company is developing for the treatment of muco-obstructive lung diseases, at the European Respiratory International Congress 2022.
-
Aytu BioPharma to Participate in September 2022 Investor Conferences
8/24/2022
Aytu BioPharma, Inc. today announced that Aytu's management team will virtually present at, and participate in, the upcoming H.C. Wainwright 24th Annual Global Investment Conference and Lytham Partners Fall 2022 Investor Conference.
-
Ainos Submits Investigational New Drug Application to the U.S. FDA to Conduct Phase 2 Trial of its VELDONA Low-dose Oral Interferon Formulation Against Mild COVID-19 Symptoms
8/24/2022
Ainos, Inc. today announced it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for conducting a Phase 2 trial of its low-dose oral interferon (IFN)-alpha formulation, VELDONA®, for treatment of mild symptoms related to COVID-19.
-
Cloud DX Webinar on Q2 Financials and Future Business
8/23/2022
Cloud DX (TSXV:CDX)(OTCQB:CDXFF), will post its Q2 financial results after market open on August 29, 2022.
-
Pharnext Announces a €2.5m Loan Agreement with Néovacs
8/23/2022
Pharnext SA, an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, announces the signing of a €2.5 million loan agreement with Néovacs, a French biotechnology company listed on Euronext Growth Paris.
-
Zomedica Appoints Dr. Pamela Nichols, DVM to Board of Directors
8/23/2022
Zomedica Corp. announced that Pamela Nichols, DVM has been appointed to its Board of Directors and is joining the Audit and Governance committees.